Topics

Lilly and Novo Nordisk Question FDA’s Draft Guidance on Insulin Biosimilars

19:00 EST 11 Feb 2020 | BioSpace

In November 2019, the U.S. Food and Drug Administration (FDA) released new draft guidance that would help generic drug companies bring biosimilars to insulin to the market more quickly. And now there are reports that two of the three primary biopharma companies that sell insulin in the U.S. are t...

Original Article: Lilly and Novo Nordisk Question FDA’s Draft Guidance on Insulin Biosimilars

NEXT ARTICLE

More From BioPortfolio on "Lilly and Novo Nordisk Question FDA’s Draft Guidance on Insulin Biosimilars"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...